Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Oncolytics Biotech stock

Own Oncolytics Biotech stock in just a few minutes.

Oncolytics Biotech Inc is a biotechnology business based in the US. Oncolytics Biotech shares (ONCY) are listed on the NASDAQ and all prices are listed in US Dollars. Oncolytics Biotech employs 25 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Oncolytics Biotech

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ONCY – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Oncolytics Biotech share price

Use our graph to track the performance of ONCY stocks over time.

Oncolytics Biotech shares at a glance

Information last updated 2021-03-10.
52-week range$0.94 - $4.19
50-day moving average $2.93
200-day moving average $2.41
Wall St. target priceN/A
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.83

Buy Oncolytics Biotech shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Oncolytics Biotech stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Oncolytics Biotech financials

Gross profit TTM $0
Return on assets TTM -58.93%
Return on equity TTM -182.63%
Profit margin 0%
Book value $0.40
Market capitalisation $145.6 million

TTM: trailing 12 months

Shorting Oncolytics Biotech shares

There are currently 891,018 Oncolytics Biotech shares held short by investors – that's known as Oncolytics Biotech's "short interest". This figure is 7.5% up from 828,747 last month.

There are a few different ways that this level of interest in shorting Oncolytics Biotech shares can be evaluated.

Oncolytics Biotech's "short interest ratio" (SIR)

Oncolytics Biotech's "short interest ratio" (SIR) is the quantity of Oncolytics Biotech shares currently shorted divided by the average quantity of Oncolytics Biotech shares traded daily (recently around 1.4 million). Oncolytics Biotech's SIR currently stands at 0.65. In other words for every 100,000 Oncolytics Biotech shares traded daily on the market, roughly 650 shares are currently held short.

However Oncolytics Biotech's short interest can also be evaluated against the total number of Oncolytics Biotech shares, or, against the total number of tradable Oncolytics Biotech shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Oncolytics Biotech's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Oncolytics Biotech shares in existence, roughly 20 shares are currently held short) or 0.0194% of the tradable shares (for every 100,000 tradable Oncolytics Biotech shares, roughly 19 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Oncolytics Biotech.

Find out more about how you can short Oncolytics Biotech stock.

Oncolytics Biotech share dividends

We're not expecting Oncolytics Biotech to pay a dividend over the next 12 months.

Have Oncolytics Biotech's shares ever split?

Oncolytics Biotech's shares were split on a 10:95 basis on 24 May 2018. So if you had owned 95 shares the day before before the split, the next day you'd have owned 10 shares. This wouldn't directly have changed the overall worth of your Oncolytics Biotech shares – just the quantity. However, indirectly, the new 850% higher share price could have impacted the market appetite for Oncolytics Biotech shares which in turn could have impacted Oncolytics Biotech's share price.

Oncolytics Biotech share price volatility

Over the last 12 months, Oncolytics Biotech's shares have ranged in value from as little as $0.94 up to $4.19. A popular way to gauge a stock's volatility is its "beta".

ONCY.US volatility(beta: 1.93)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Oncolytics Biotech's is 1.9314. This would suggest that Oncolytics Biotech's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Oncolytics Biotech overview

Oncolytics Biotech Inc. , a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an immuno-oncology viral-agent for the treatment of solid tumors and hematological malignancies. The company has collaboration agreements with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone-receptor positive, human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. Oncolytics Biotech Inc. was founded in 1998 and is headquartered in Calgary, Canada.

Frequently asked questions

What percentage of Oncolytics Biotech is owned by insiders or institutions?
Currently 1.24% of Oncolytics Biotech shares are held by insiders and 1.852% by institutions.
How many people work for Oncolytics Biotech?
Latest data suggests 25 work at Oncolytics Biotech.
When does the fiscal year end for Oncolytics Biotech?
Oncolytics Biotech's fiscal year ends in December.
Where is Oncolytics Biotech based?
Oncolytics Biotech's address is: 1167 Kensington Crescent NW, Calgary, AB, Canada, T2N 1X7
What is Oncolytics Biotech's ISIN number?
Oncolytics Biotech's international securities identification number is: CA6823108759
What is Oncolytics Biotech's CUSIP number?
Oncolytics Biotech's Committee on Uniform Securities Identification Procedures number is: 682310875

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site